Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Tetracaine/Oxymetazoline Nasal Spray for Endodontic Treatment
NCT03502135Phase 4Withdrawn
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Sep 2018
- Primary completion
- Jun 2019
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 4, open-label, single-arm trial of tetracaine HCl + oxymetazoline HCl in endodontic disease, sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Proportion of patients that are successfully anesthetized for endodontic treatment. Planned start Sep 2018; status: withdrawn.
02
Drugs
tetracaine HCl + oxymetazoline HCl
03
Conditions
endodontic disease
Beyond the preview
Go deeper on NCT03502135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502135.